A randomised phase II study of weekly paclitaxel or vinorelbine in combination with cisplatin against inoperable non-small-cell lung cancer previously untreated

British Journal of Cancer

Volumn 90, Issue 2, 2004, Pages 359-365

  Chen, Y M ^a,b   Perng, R P ^a,b   Shih, J F ^a,b   Lee, Y C ^a,b   Lee, C S ^a,b   Tsai, C M ^a,b   Whang Peng, J ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Cisplatin; Non small cell lung cancer; Paclitaxel; Vinorelbine

Indexed keywords

CISPLATIN; NAVELBINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; VINBLASTINE;

EID: 1342301553     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601526     Document Type: Article

References (23)

1. Akerley W, Glantz M, Choy H, Rege V, Sambandam S, Joseph P, Yee L, Rodrigues B, Wingate P, Leone L (1998) Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 16: 153-158
2. Baggstrom MQ, Socinski MA, Hensing TA, Poole C (2002) Third-generation chemotherapy regimens (3GR) improve survival over second-generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol 21: a1222
3. Belani CP (2001) Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer. Semin Oncol 28(Suppl 14): 14-16
4. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631
5. Chang AY, Rubins J, Asbury R, Boros L, Hui LF (2001) Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol 28(Suppl 14): 10-13
6. Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, DeMarinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G (2000) Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 18: 3390-3399
7. Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, Pennucci MC, Scagliotti G, van Meerbeeck J, van Hoesel Q, Curran D, Sahmoud T, Postmus PE (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133-2141
8. Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11: 1866-1872
9. Hollen PJ, Gralla RJ (1996) Comparison of instruments for measuring quality of life in patients with lung cancer. Semin Oncol 23(Suppl 5): 31-40
10. Koumakis G, Demiri M, Barbounis V, Vassilomanolakis M, Gontikakis E, Pamouksoglou P, Dahabre J, Efremidis AP (2002) Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial. Lung Cancer 35: 315-317
11. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367
12. Lutz ST, Huang DT, Ferguson CL, Kavanagh BD, Tercilla OF, Lu J (1997) A retrospective quality of life analysis using the Lung Cancer Symptom Scale in patients treated with palliative radiotherapy for advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 37: 117-122
13. Non-small cell lung cancer (NSCLC) collaborative group (1995) Chemotherapy in non-small cell lung cancer, a meta-analysis using updated data in individual patients from 52 randomized trials. Br Med J 311: 899-909
14. Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. Ca Cancer J Clin 49: 33-64
15. Perng RP, Shih JF, Chen YM, Delgado FM, Tsai CM, Chou KC, Liu JM, Chern MS, Whang-Peng J (2000) A phase II trial of vinorelbine and cisplatin in previously untreated inoperable non-small cell lung cancer. Am J Clin Oncol 23: 60-64
16. Raftopoulos H, Gralla RJ, Bria E, Eid A (2002) Assessing the role of chemotherapy in advanced non-small cell lung cancer (NSCLC): a comprehensive review of large randomised trials 1991-2001. Proc Am Soc Clin Oncol 21: a1284
17. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA, Rivkin SE, Kelly K, Gandara DR (2002) Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 94: 291-297
18. Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, Matano E, Boni C, Marangolo M, Failla G, Altavilla G, Adamo V, Ceribelli A, Clerici M, Di Costanzo F, Frontini L, Tonato M (2002) Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20: 4285-4291
19. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98
20. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147
21. Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69: 1375-1381
22. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva, Switzerland: World Health Organization
23. Yana T, Takada M, Origasa H, Ijima T, Yamamoto N, Nakagawa K, Fukuoka M (2002) New chemotherapy agent plus platinum for advanced non-small cell lung cancer: a meta-analysis. Proc Am Soc Clin Oncol 21: a1309